(JP2016196513) PROBLEM TO BE SOLVED: To provide methods and compositions for treating complement-associated disorders.SOLUTION: The disclosure relates to, inter alia, compositions comprising an inhibitor of human complement, and to the use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in the amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions comprise an antibody or antigen-binding fragment thereof that binds to a human complement component C5 protein or fragments of the protein such as C5a or C5b.SELECTED DRAWING: None
(JP2016196513) LEGAL DETAILS FOR JP2016196513 Actual or expected expiration date=2029-11-10 Legal state=ALIVE Status=PENDING Event publication date=2016-08-29 Event code=JP/APP Event indicator=Pos Event type=Examination events Application details Application country=JP JP2016166460 Application date=2016-08-29 Standardized application number=2016JP-0166460 Event publication date=2016-08-31 Event code=JP/A621 Event indicator=Pos Event type=Examination events Written request for application examination Effective date of the event=2016-08-29 JAPANESE INTERMEDIATE CODE: A621 Event publication date=2016-11-24 Event code=JP/A Event indicator=Pos Event type=Examination events Published application Publication country=JP Publication number=JP2016196513 Publication stage Code=A Publication date=2016-11-24 Standardized publication number=JP2016196513 Event publication date=2017-05-22 Event code=JP/A131 Event indicator=Neg Event type=Examination events Notification of reasons for refusal Effective date of the event=2017-05-22 JAPANESE INTERMEDIATE CODE: A131 Event publication date=2017-07-14 Event code=JP/A601 Event type=Examination events Written request for extension of term Effective date of the event=2017-07-14 JAPANESE INTERMEDIATE CODE: A601
最新评论
暂无评论。